Fremont 2.0

The project scope involved the establishment of in-house competitive stem cell technology in Fremont to ensure cGMP production capacity for gene edited stem cell-based therapies for both non-clinical, clinical trials and launch for market.
The project included 1st level lab upgrades and refresh open office and private office spaces and on the 2nd level, conversion of existing labs to additional cleanroom as part of existing suite associated mechanical, plumbing and process piping and electrical upgrades.